BASHAN DROR (President & CEO) received a stock award from PROTALIX BIOTHERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 9/4/2025ACC: 0001415889-25-023700
DirectorOfficer· President & CEO
Since Jun 2019
+535K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
535K acquired
Non-Derivative Transactions1
Common Stock
Indirect
Shares
+195K
Price / share
—
Trade value
—
% of position
9.1%
9/3/2025
2.15M→2.34M
Total
Net shares
+195K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 9/3/2025 | A · Award | +195K | — | — | 9.1% | 2.15M | 2.34M |
| Total | +195K | $0.00 | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
340K shares
Shares
+340K
Strike price
1.64
Held after
340K
Exercisable
—
9/3/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock340K shares | 9/3/2025 | A · Award | +340K | 1.64 | — | 340K |
Non-Derivative Holdings (Post-Transaction)1
Common Stock
DirectShares owned132.52K
Total
132.52K direct132.52K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 132.52K | Direct |
| Total | 132.52K | 132.52K direct |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported